Rhumbline Advisers Increases Holdings in Can-Fite BioPharma Ltd. (NYSE:CANF)

Rhumbline Advisers raised its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the quarter. Rhumbline Advisers owned about 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent quarter.

Analysts Set New Price Targets

A number of brokerages have issued reports on CANF. StockNews.com began coverage on Can-Fite BioPharma in a research note on Friday, March 7th. They set a “sell” rating for the company. D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Can-Fite BioPharma in a research note on Monday, March 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th.

Can-Fite BioPharma Trading Up 2.9 %

Can-Fite BioPharma stock opened at $1.58 on Wednesday. The firm has a market cap of $5.58 million, a price-to-earnings ratio of -0.88 and a beta of 1.12. The stock has a fifty day simple moving average of $1.59 and a two-hundred day simple moving average of $1.91. Can-Fite BioPharma Ltd. has a 12 month low of $1.29 and a 12 month high of $4.69.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.